Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy

Diabetologia

Volumn 52, Issue 5, 2009, Pages 972-981

  Yang, S J ^a   Iglayreger, H B ^a   Kadouh, H C ^b   Bodary, P F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

CCL2 CCR2 pathway; Hepatic steatosis; Inflammation; Lipoatrophic diabetes

Indexed keywords

CD68 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CHOLESTEROL; GLUCOSE; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RS 504393; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL MOUSE; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS; HEPATOMEGALY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOATROPHIC DIABETES MELLITUS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WILD TYPE;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, LIPOATROPHIC; DISEASE MODELS, ANIMAL; FATTY LIVER; FEMALE; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; ORGAN SIZE; RECEPTORS, CCR2; TRANSCRIPTION FACTORS;

EID: 64149125118     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1309-8     Document Type: Article

References (38)

1. BA Neuschwander-Tetri SH Caldwell 2003 Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 1202 1219
2. RS Rector JP Thyfault Y Wei JA Ibdah 2008 Non-alcoholic fatty liver disease and the metabolic syndrome: an update World J Gastroenterol 14 185 192
3. H Yki-Jarvinen J Westerbacka 2005 The fatty liver and insulin resistance Curr Mol Med 5 287 295
4. IR Wanless JS Lentz 1990 Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 12 1106 1110
5. OP Ganda 2000 Lipoatrophy, lipodystrophy, and insulin resistance Ann Intern Med 133 304 306
6. M Seip O Trygstad 1996 Generalized lipodystrophy, congenital and acquired (lipoatrophy) Acta Paediatr Suppl 413 2 28
7. JK Kim O Gavrilova Y Chen ML Reitman GI Shulman 2000 Mechanism of insulin resistance in A-ZIP/F-1 fatless mice J Biol Chem 275 8456 8460
8. SE Shoelson J Lee AB Goldfine 2006 Inflammation and insulin resistance J Clin Invest 116 1793 1801
9. SP Weisberg D McCann M Desai M Rosenbaum RL Leibel AW Ferrante Jr 2003 Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 112 1796 1808
10. H Xu GT Barnes Q Yang 2003 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 1821 1830
11. M Krebs M Roden 2005 Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature Diabetes Obes Metab 7 621 632
12. J Delarue C Magnan 2007 Free fatty acids and insulin resistance Curr Opin Clin Nutr Metab Care 10 142 148
13. G Boden P She M Mozzoli 2005 Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver Diabetes 54 3458 3465
14. JW Haukeland JK Damas Z Konopski 2006 Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2 J Hepatol 44 1167 1174
15. J Westerbacka M Kolak T Kiviluoto 2007 Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects Diabetes 56 2759 2765
16. H Kanda S Tateya Y Tamori 2006 MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity J Clin Invest 116 1494 1505
17. SP Weisberg D Hunter R Huber 2006 CCR2 modulates inflammatory and metabolic effects of high-fat feeding J Clin Invest 116 115 124
18. J Moitra MM Mason M Olive 1998 Life without white fat: a transgenic mouse Genes Dev 12 3168 3181
19. H Tilg AR Moschen 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity Nat Rev Immunol 6 772 783
20. G Fantuzzi 2005 Adipose tissue, adipokines, and inflammation J Allergy Clin Immunol 115 911 919
21. M Kolak J Westerbacka VR Velagapudi 2007 Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity Diabetes 56 1960 1968
22. I Dahlman M Kaaman T Olsson 2005 A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects J Clin Endocrinol Metab 90 5834 5840
23. CS Kim HS Park T Kawada 2006 Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters Int J obesity 30 1347 1355
24. C Herder J Baumert B Thorand 2006 Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002 Diabetologia 49 921 929
25. JI Barzilay L Abraham SR Heckbert 2001 The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study Diabetes 50 2384 2389
26. H Chen A Ren S Hu W Mo X Xin W Jia 2007 The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment Diabetes Res Clin Pract 75 327 332
27. KE Inouye H Shi JK Howard 2007 Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue Diabetes 56 2242 2250
28. Y Tamura M Sugimoto T Murayama 2008 Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice Arterioscler Thromb Vasc Biol 28 2195 2201
29. K Wouters PJ van Gorp V Bieghs 2008 Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis Hepatology 48 474 486
30. K Furuichi T Wada Y Iwata 2003 CCR2 signaling contributes to ischemia-reperfusion injury in kidney J Am Soc Nephrol 14 2503 2515
31. K Kitagawa T Wada K Furuichi 2004 Blockade of CCR2 ameliorates progressive fibrosis in kidney Am J Pathol 165 237 246
32. Higgins P, Schwartz E, Nicolas J (2007) Small molecule CCR2 antagonists. In: Neote K, Letts G, Moser B (eds) Chemokine biology-basic research and clinical application. Birkhauser, Basel, pp 115-123
33. H Kanamori T Matsubara A Mima 2007 Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy Biochem Biophys Res Commun 360 772 777
34. DM Dambach LM Watson KR Gray SK Durham DL Laskin 2002 Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse Hepatology 35 1093 1103
35. KL Hokeness WA Kuziel CA Biron TP Salazar-Mather 2005 Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver J Immunol 174 1549 1556
36. J Arun RH Clements AJ Lazenby RR Leeth GA Abrams 2006 The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women Obes Surg 16 1351 1358
37. BW Walsh I Schiff B Rosner L Greenberg V Ravnikar FM Sacks 1991 Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins N Engl J Med 325 1196 1204
38. S Grimbert C Fisch D Deschamps 1995 Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy Am J Physiol 268 G107 G115